TABLE 3.
Univariate and multivariate analyses of severe RILTs (grade ≥3) in patients with stage III non‐small‐cell lung cancer treated with thoracic radiation (n = 85)
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | p‐value | Odds ratio | 95% CI | p‐value | |
| Age, y (≥65 vs. <65) | 0.65 | 0.22–1.91 | 0.438 | |||
| Performance status (2 vs. 1) | 0.56 | 0.20–1.69 | 0.314 | |||
| Smoking history (never vs. current or former smoker) | 1.73 | 0.36–8.73 | 0.482 | |||
| Honeycombing score on CT (0–1 vs. 2–3) | 4.40 | 1.43–13.53 | 0.010 | 4.53 | 1.39–14.77 | 0.012 |
| mGAP score (>3 vs. ≤3) (n = 73) | 0.48 | 0.12–1.95 | 0.305 | |||
| Clinical stage (IIIB vs. IIIA) | 1.68 | 0.53–5.30 | 0.376 | |||
| Histology (squamous vs. non‐squamous) | 0.75 | 0.25–2.22 | 0.599 | |||
| Tumor location (lower lobe vs. non‐lower lobe) | 1.28 | 0.43–3.80 | 0.653 | |||
| %FVC (<75% vs. ≥75%) (n = 73) | 0.96 | 0.27–3.37 | 0.951 | |||
| MLD (<13.71 Gy vs. ≥13.71 Gy) (n = 83) | 2.07 | 0.69–6.26 | 0.197 | |||
| V5 (≥55% vs. <55%) (n = 83) | 1.89 | 0.64–5.58 | 0.250 | |||
| V20 (≥20% vs. <20%) (n = 83) | 10.00 | 1.25–80.14 | 0.030 | 9.40 | 1.13–77.89 | 0.038 |
| Treatment (cCRT vs. sCRT or RT alone) | 2.83 | 0.86–9.25 | 0.086 | |||
| Paclitaxel or gemcitabine vs. other chemotherapy | 2.10 | 0.54–8.18 | 0.285 | |||
Abbreviations: RILTs, radiation induced lung toxicities; mGAP, modified age gender, and pulmonary physiology index; FVC, forced vital capacity; MLD, mean lung dose; V5, the percentage of lung volume minus gross tumor volume receiving >5 Gy; V20, the percentage of lung volume minus gross tumor volume receiving >20 Gy; cCRT, concurrent chemoradiotherapy; sCRT, sequential chemoradiotherapy; RT, radiotherapy.